BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29097932)

  • 1. High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26.
    Mitran B; Thisgaard H; Rosenström U; Dam JH; Larhed M; Tolmachev V; Orlova A
    Contrast Media Mol Imaging; 2017; 2017():6873684. PubMed ID: 29097932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
    Baun C; Mitran B; Rinne SS; Dam JH; Olsen BB; Tolmachev V; Orlova A; Thisgaard H
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33352838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.
    Varasteh Z; Aberg O; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Antoni G; Sandström M; Tolmachev V; Orlova A
    PLoS One; 2013; 8(12):e81932. PubMed ID: 24312607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.
    Mitran B; Varasteh Z; Selvaraju RK; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Rosenström U; Orlova A
    Int J Oncol; 2016 May; 48(5):2124-34. PubMed ID: 26983776
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
    Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
    Mitran B; Thisgaard H; Rinne S; Dam JH; Azami F; Tolmachev V; Orlova A; Rosenström U
    Sci Rep; 2019 Nov; 9(1):17086. PubMed ID: 31745219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
    Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
    Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
    Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.
    Varasteh Z; Velikyan I; Lindeberg G; Sörensen J; Larhed M; Sandström M; Selvaraju RK; Malmberg J; Tolmachev V; Orlova A
    Bioconjug Chem; 2013 Jul; 24(7):1144-53. PubMed ID: 23763444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
    Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
    Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a novel GRPR antagonist for prostate cancer PET imaging: [
    Mansour N; Paquette M; Ait-Mohand S; Dumulon-Perreault V; Guérin B
    Nucl Med Biol; 2018 Jan; 56():31-38. PubMed ID: 29154145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog.
    Dijkgraaf I; Franssen GM; McBride WJ; D'Souza CA; Laverman P; Smith CJ; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Jun; 53(6):947-52. PubMed ID: 22570329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.
    Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y
    Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Novel [
    Kanellopoulos P; Bezverkhniaia E; Abouzayed A; Rosenström U; Tolmachev V; Orlova A
    ACS Omega; 2024 Apr; 9(16):18608-18616. PubMed ID: 38680331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics.
    Abouzayed A; Kanellopoulos P; Gorislav A; Tolmachev V; Maina T; Nock BA; Orlova A
    Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.
    Varasteh Z; Rosenström U; Velikyan I; Mitran B; Altai M; Honarvar H; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
    Molecules; 2014 Jul; 19(7):10455-72. PubMed ID: 25036155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer.
    Liu Z; Li ZB; Cao Q; Liu S; Wang F; Chen X
    J Nucl Med; 2009 Jul; 50(7):1168-77. PubMed ID: 19525469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
    Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
    J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.